Literature DB >> 2733706

Movement disorders and depression due to flunarizine and cinnarizine.

F E Micheli1, M M Pardal, R Giannaula, M Gatto, I Parera, G Paradiso, M Torres, R Pikielny, J Pardal.   

Abstract

Over the last few years, cases of movement disorders induced by flunarizine and cinnarizine have been increasingly reported. We describe a series of 101 patients, whose ages ranged from 37 to 84 years (mean 69.1), developing abnormal movements frequently associated with depression, secondary to treatment with either or both drugs. Symptoms closely resembled those induced by neuroleptic drugs and remitted on drug discontinuance in all but five cases after 5-22 months' follow-up. Whether or not such undesirable side effects are attributable to calcium antagonism and/or dopamine receptor blockade, long-term treatment with flunarizine or cinnarizine should be discouraged, particularly in the elderly.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2733706     DOI: 10.1002/mds.870040205

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  15 in total

Review 1.  Essential tremor.

Authors:  Joaquim Jos Ferreira; Cristina Sampaio
Journal:  BMJ Clin Evid       Date:  2007-05-01

2.  A postmarketing study of flunarizine in migraine and vertigo.

Authors:  G H de Bock; J Eelhart; H W van Marwijk; T P Tromp; M P Springer
Journal:  Pharm World Sci       Date:  1997-12

3.  Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study.

Authors:  Hsiu-Li Lin; Hsiu-Chen Lin; Yuan-Fu Tseng; Shih-Chang Chen; Chien-Yeh Hsu
Journal:  Eur J Clin Pharmacol       Date:  2016-12-16       Impact factor: 2.953

4.  Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype.

Authors:  Renato P Munhoz; Delcio Bertucci Filho; Hélio A G Teive
Journal:  Neurol Sci       Date:  2016-11-16       Impact factor: 3.307

Review 5.  Diagnosis and treatment of Parkinson's disease in the elderly.

Authors:  J I Sage; M H Mark
Journal:  J Gen Intern Med       Date:  1994-10       Impact factor: 5.128

Review 6.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 7.  Antiparkinsonian agents. Drug interactions of clinical significance.

Authors:  R F Pfeiffer
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

8.  Nimodipine in migraine: clinical efficacy and endocrinological effects.

Authors:  R Formisano; P Falaschi; R Cerbo; A Proietti; T Catarci; R D'Urso; C Roberti; V Aloise; F Chiarotti; A Agnoli
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 9.  Drug-induced depression. Incidence, avoidance and management.

Authors:  S B Patten; E J Love
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

Review 10.  Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.